<DOC>
	<DOCNO>NCT00172042</DOCNO>
	<brief_summary>30-40 % patient lung cancer develop bone metastasis course disease , lead pain , decrease mobility skeletal complication . This study investigate effect zoledronic acid prevent delay development bone metastases impact disease progression/survival patient stage IIIA IIIB Non-small Cell Lung Cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Zoledronic Acid Prevention Delaying Bone Metastasis Patients With Stage IIIA IIIB Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Histologically cytologically confirm Nonsmall Cell Lung Cancer ( NSCLC ) Newly Diagnosed , Stage IIIA Stage IIIB exclude patient pleural effusion Patients must receive primary treatment disease progression Diagnosed NSCLC longer 6 month ago Treatment bisphosphonates past 12 month Presence metastases Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Non-Small-Cell Lung Cancer</keyword>
	<keyword>Bisphosphonates</keyword>
	<keyword>Zoledronic acid</keyword>
	<keyword>Bone metastasis</keyword>
	<keyword>Prevention bone metastasis</keyword>
</DOC>